Consolidated Statement of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
Research and development	$ 6,336,075	$ 15,489,997
General and administrative	4,314,164	7,431,108
Change in fair value of related party note	638,046
Operating loss	(11,288,285)	(22,921,105)
Other income (expense), net:
Interest income, net	172,568	463,256
Other income (expense), net	330,915	(10)
Net loss	$ (10,784,802)	$ (22,457,859)
Per common share data:
Basic net loss per common share	$ (2.86)	$ (6.54)
Diluted net loss per common share	$ (2.86)	$ (6.54)
Weighted average number of common shares outstanding, basic	3,773,326	3,435,994
Weighted average number of common shares outstanding, diluted	3,773,326	3,435,994
Other comprehensive loss
Foreign currency translation loss	$ (200,629)	$ (138,479)
Comprehensive loss	$ (10,985,431)	$ (22,596,338)